Impedimed Ltd (IPD) - Net Assets
Based on the latest financial reports, Impedimed Ltd (IPD) has net assets worth AU$10.19 Million AUD (≈ $7.21 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$34.66 Million ≈ $24.52 Million USD) and total liabilities (AU$24.47 Million ≈ $17.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check IPD strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$10.19 Million |
| % of Total Assets | 29.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | -80.04% |
| 10-Year Change | -82.67% |
| Growth Volatility | 68.26 |
Impedimed Ltd - Net Assets Trend (2006–2026)
This chart illustrates how Impedimed Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of Impedimed Ltd.
Annual Net Assets for Impedimed Ltd (2006–2026)
The table below shows the annual net assets of Impedimed Ltd from 2006 to 2026. Also explore IPD net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-06-30 | AU$10.19 Million ≈ $7.21 Million |
-50.30% |
| 2025-06-30 | AU$20.50 Million ≈ $14.50 Million |
-49.69% |
| 2024-06-30 | AU$40.74 Million ≈ $28.83 Million |
-33.08% |
| 2023-06-30 | AU$60.88 Million ≈ $43.08 Million |
+19.27% |
| 2022-06-30 | AU$51.04 Million ≈ $36.12 Million |
+100.06% |
| 2021-06-30 | AU$25.51 Million ≈ $18.05 Million |
-6.75% |
| 2020-06-30 | AU$27.36 Million ≈ $19.36 Million |
+73.34% |
| 2019-06-30 | AU$15.79 Million ≈ $11.17 Million |
-55.91% |
| 2018-06-30 | AU$35.80 Million ≈ $25.33 Million |
-39.11% |
| 2017-06-30 | AU$58.80 Million ≈ $41.60 Million |
-31.03% |
| 2016-06-30 | AU$85.25 Million ≈ $60.32 Million |
+144.72% |
| 2015-06-30 | AU$34.84 Million ≈ $24.65 Million |
+157.44% |
| 2014-06-30 | AU$13.53 Million ≈ $9.57 Million |
+27.73% |
| 2013-06-30 | AU$10.59 Million ≈ $7.50 Million |
-38.80% |
| 2012-06-30 | AU$17.31 Million ≈ $12.25 Million |
-16.31% |
| 2011-06-30 | AU$20.68 Million ≈ $14.63 Million |
-6.96% |
| 2010-06-30 | AU$22.23 Million ≈ $15.73 Million |
+120.82% |
| 2009-06-30 | AU$10.07 Million ≈ $7.12 Million |
-18.16% |
| 2008-06-30 | AU$12.30 Million ≈ $8.70 Million |
-36.61% |
| 2007-06-30 | AU$19.40 Million ≈ $13.73 Million |
+514.69% |
| 2006-06-30 | AU$-4.68 Million ≈ $-3.31 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Impedimed Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 34728738100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$349.86 Million | 3434.38% |
| Other Comprehensive Income | AU$39.42 Million | 386.99% |
| Total Equity | AU$10.19 Million | 100.00% |
Impedimed Ltd Competitors by Market Cap
The table below lists competitors of Impedimed Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SILVER DOLLAR RES
F:4YW
|
$12.96 Million |
|
Nosa Med AB
ST:NOSA
|
$12.96 Million |
|
Eratex Djaja Tbk
JK:ERTX
|
$12.97 Million |
|
Bd Multimedia
PA:ALBDM
|
$12.97 Million |
|
Bytes Technology Ltd
LSE:BYIT
|
$12.96 Million |
|
Ugint Co Ltd
KQ:195990
|
$12.95 Million |
|
Pluri Inc.
NASDAQ:PLUR
|
$12.95 Million |
|
Thunderful Group AB
ST:THUNDR
|
$12.95 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Impedimed Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 20,496,000 to 10,187,000, a change of -10,309,000 (-50.3%).
- Net loss of 24,907,000 reduced equity.
- Share repurchases of 1,768,000 reduced equity.
- New share issuances of 15,300,000 increased equity.
- Other comprehensive income increased equity by 885,000.
- Other factors increased equity by 181,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-24.91 Million | -244.5% |
| Share Repurchases | AU$1.77 Million | -17.36% |
| Share Issuances | AU$15.30 Million | +150.19% |
| Other Comprehensive Income | AU$885.00K | +8.69% |
| Other Changes | AU$181.00K | +1.78% |
| Total Change | AU$- | -50.30% |
Book Value vs Market Value Analysis
This analysis compares Impedimed Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.02x to 1.05x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-06-30 | AU$0.23 | AU$0.01 | x |
| 2008-06-30 | AU$0.17 | AU$0.01 | x |
| 2009-06-30 | AU$0.10 | AU$0.01 | x |
| 2010-06-30 | AU$0.18 | AU$0.01 | x |
| 2011-06-30 | AU$0.13 | AU$0.01 | x |
| 2012-06-30 | AU$0.10 | AU$0.01 | x |
| 2013-06-30 | AU$0.05 | AU$0.01 | x |
| 2014-06-30 | AU$0.06 | AU$0.01 | x |
| 2015-06-30 | AU$0.12 | AU$0.01 | x |
| 2016-06-30 | AU$0.27 | AU$0.01 | x |
| 2017-06-30 | AU$0.16 | AU$0.01 | x |
| 2018-06-30 | AU$0.09 | AU$0.01 | x |
| 2019-06-30 | AU$0.04 | AU$0.01 | x |
| 2020-06-30 | AU$0.05 | AU$0.01 | x |
| 2021-06-30 | AU$0.02 | AU$0.01 | x |
| 2022-06-30 | AU$0.03 | AU$0.01 | x |
| 2023-06-30 | AU$0.03 | AU$0.01 | x |
| 2024-06-30 | AU$0.02 | AU$0.01 | x |
| 2025-06-30 | AU$0.01 | AU$0.01 | x |
| 2026-06-30 | AU$0.00 | AU$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Impedimed Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -244.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -170.44%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 3.40x
- Recent ROE (-244.50%) is below the historical average (-80.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -79.30% | -422.00% | 0.16x | 1.18x | AU$-10.98 Million |
| 2009 | -139.34% | -468.85% | 0.23x | 1.30x | AU$-15.03 Million |
| 2010 | -51.29% | -313.33% | 0.15x | 1.12x | AU$-13.62 Million |
| 2011 | -71.66% | -381.32% | 0.17x | 1.10x | AU$-16.89 Million |
| 2012 | -71.30% | -419.08% | 0.15x | 1.13x | AU$-14.07 Million |
| 2013 | -79.89% | -309.70% | 0.23x | 1.12x | AU$-9.52 Million |
| 2014 | -58.64% | -225.36% | 0.24x | 1.11x | AU$-9.29 Million |
| 2015 | -42.47% | -305.47% | 0.13x | 1.09x | AU$-18.28 Million |
| 2016 | -30.47% | -448.63% | 0.06x | 1.06x | AU$-34.51 Million |
| 2017 | -46.89% | -478.17% | 0.09x | 1.09x | AU$-33.45 Million |
| 2018 | -76.10% | -821.22% | 0.08x | 1.16x | AU$-30.83 Million |
| 2019 | -152.02% | -577.38% | 0.18x | 1.43x | AU$-25.57 Million |
| 2020 | -78.13% | -372.36% | 0.17x | 1.21x | AU$-24.11 Million |
| 2021 | -81.16% | -246.24% | 0.25x | 1.34x | AU$-23.26 Million |
| 2022 | -38.94% | -188.09% | 0.18x | 1.15x | AU$-24.98 Million |
| 2023 | -33.71% | -180.90% | 0.17x | 1.13x | AU$-26.61 Million |
| 2024 | -48.57% | -191.78% | 0.22x | 1.15x | AU$-23.86 Million |
| 2025 | -113.37% | -182.62% | 0.31x | 2.03x | AU$-25.29 Million |
| 2026 | -244.50% | -170.44% | 0.42x | 3.40x | AU$-25.93 Million |
Industry Comparison
This section compares Impedimed Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $42,207,327
- Average return on equity (ROE) among peers: -28.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Impedimed Ltd (IPD) | AU$10.19 Million | -79.30% | 2.40x | $12.96 Million |
| 4DMEDICAL Ltd (4DX) | $-11.81 Million | 0.00% | 0.00x | $1.75 Billion |
| Adherium Ltd (ADR) | $34.53 Million | -3.63% | 0.08x | $3.18 Million |
| Aroa Biosurgery Ltd (ARX) | $84.59 Million | -4.10% | 0.17x | $130.04 Million |
| Atomo Diagnostics Ltd (AT1) | $34.48 Million | -26.73% | 0.05x | $11.49 Million |
| Avita Medical Inc (AVH) | $124.47 Million | -31.47% | 0.16x | $188.51 Million |
| Anteris Technologies Global Corp (AVR) | $101.28 Million | -121.71% | 0.29x | $809.31 Million |
| Control Bionics Ltd (CBL) | $20.13 Million | -5.00% | 0.02x | $23.82 Million |
| Cardiex Ltd (CDX) | $1.88 Million | -105.36% | 1.22x | $13.23 Million |
| Compumedics Ltd (CMP) | $9.21 Million | -30.70% | 1.16x | $33.22 Million |
| Cochlear Ltd (COH) | $23.31 Million | 46.38% | 1.20x | $6.20 Billion |
About Impedimed Ltd
ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) technology medical devices and software services in Australia, Europe, the United States, and internationally. The company offers SOZO, a noninvasive BIS device for the clinical assessment of lymphedema, which uses bioimpedance measurements to assess fluid levels and tissue compositi… Read more